Thor Halfdanarson, Professor of Oncology at Mayo Clinic, shared on X:
“More on the topic of carcinoid crisis (CC), this time relating to the use of PRRT. I struggle a little with this one. We keep hearing about carcinoid crisis after PRRT but just like with surgery, it is less common than previously thought.
We are reviewing >800 patients who had PRRT (safe to say that 25-30% of them had a functional tumor) and I do not recall a single case of a crisis following PRRT. Naturally, nearly all patients with functional NETs are on long-acting SSAs at the time of therapy for syndrome control but always 4+ weeks away from the most recent injection.
Almost no one is on short acting SSAs and most have a long-acting injection within 4-5 hours of the PRRT, before leaving the facility. Pheo/Para are a different beast though. There, crises are very real, not common, and can be life threatening. Not saying CC does not happen after PRRT but we just don’t see it. Same with functional panc NET syndrome crises. If our final analysis shows crises, we will for sure report on that.”
Title: Prevention and management of hormonal crisis in neuroendocrine tumors undergoing PRRT (peptide receptor radionuclide therapy): a systematic review
Authors: G Arrivi, M Pagnanelli, G Puliani, A Zerbi, S Partelli, F Panzuto.
Read the full article.
This also can be interesting:
COMPETE Trial: [177Lu]Lu-Edotreotide Prolongs PFS vs Everolimus in Advanced GEP NETs
